different commodity play
Categories
PrimeInvestor Research Team

Stock Recommendation: A different commodity play

Sugar stocks have been fired up lately on expectations that the industry is set to turn a corner. While the sector has seen many false dawns on reform hopes in the past, the changes we are seeing this time around could turn out to be the real deal.

Premium article available only to subscribers.

Read More
risk premium, risk
Categories
Vidya Bala

Risk premium – What it is and how it helps you set return expectations

In this article, we’ll explore where risk premiums come from in debt and equity. This is important because risk premiums are not fixed and change with time. So, if you base your return expectations wrong, you may wind up with a different corpus that you originally planned to.

Premium article available only to subscribers.

Read More
LIC New Jeevan Anand, LIC New Jeevan Anand Policy
Categories
Bipin Ramachandran

What’s your return from LIC New Jeevan Anand policy?

The most popular of such endowment policies is a policy called the “LIC New Jeevan Anand”. It makes a simple, attractive proposition to its policyholders – pay a premium for ‘n’ number of years and get a fixed sum assured PLUS bonus at the end of this period. AND, when the policyholder dies post this period, the family will get the sum assured again. You benefit when you live and your family benefits when, eventually, you die!

Read More
glenmark life sciences, glenmark life sciences ipo, IPO review
Categories
N V Chandrachoodamani

IPO Review: Glenmark Life Sciences – Should you invest?

Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?

Premium article available only to subscribers.

Read More
evaluate banking and finance stocks
Investment basics
R Balakrishnan

How to evaluate banking and finance stocks

There are certain characteristics which make evaluating banking and finance stocks different from others which produce goods and services. Money cannot be lent to someone unless there is an inflow by way of capital or debt. Since it is not practical to lend only from capital, borrowing (or leverage) is the sustaining food for this business. Naturally in using this leverage, there are good and bad apples.

Premium article available only to subscribers.

Read More
1 crore, 1 crore health policy, health insurance
Categories
Aarati Krishnan

Why you don’t need a Rs 1 crore health policy

Recent reports suggest that as many as 35% of health insurance buyers in recent times – mainly in their 30s and 40s – are buying Rs 1 crore health insurance plans, against just 5% who used to buy them earlier.

Premium article available only to subscribers.

Read More
mid-and-smallcap index
Categories
B Krishnakumar

Can the rally continue in the mid-and-smallcap index?

While the benchmark Nifty 50 index has been confined to a broad trading range, the broader markets or the mid-cap and small-cap universe has been buzzing with action. Let us take a closer look at the current trend and the near-term outlook for the Nifty MidSmallcap 400 Index. We have covered this index in an earlier article, and we take a relook now.

Premium article available only to subscribers.

Read More
trends, trends and changes in our mutual fund review
Categories
PrimeInvestor Research Team

Quarterly MF review – trends and changes

In the first of our updates in this review cycle, we explained the changes we have made to Prime Funds, our recommended fund list. In this second update, we thought to cover two different aspects: one, changes we made to our MF Review Tool, in the way we call out our recommendations. Two, trends we have observed unfolding over the past couple of quarters that we’re keeping a watch on.

Read More
changes in prime funds
Categories
PrimeInvestor Research Team

Quarterly review – changes in Prime Funds, our mutual fund recommendations

We are living in strange times. No, I am not talking of Covid-19. Your one-year returns of equity funds (across categories), at an average 31% between January to March 22, 2021, zoomed to an average 69% since March 23, 2021. In other words, 1-year returns suddenly doubled from March 23, 2021. If you recall, March 23 2020 was a market low. So, 1-year returns from March 23, 2021, have started looking abnormally high.

Premium article available only to subscribers.

Read More
zomato ipo, ipo review, zomato
Categories
Bhavana Acharya

IPO Review : Zomato IPO – Invest or avoid?

If there’s talk in the stock markets today, it’s devoted to the upcoming Zomato IPO, which aims to mop up Rs 9,375 crore. Unlike the crop of recent private equity investor backed companies doing IPOs, this isn’t primarily an offer for sale. Zomato gets a whopping Rs 9,000 crore to deploy into its business mainly through a fresh issue of shares. Only one investor, Info Edge, will offload a Rs 375 crore stake. At the upper end of the price band of Rs 72-76, the post-offer market cap of listed Zomato will be around Rs 60,000 crore.

Premium article available only to subscribers.

Read More
Categories
Aarati Krishnan

2 bond offers playing on home loans – should you invest?

Home loans are one of the safer lending avenues for NBFCs, given that they are backed by collateral that usually appreciates in price. But does that make bond offers from two housing finance NBFCs – Piramal Capital and Housing Finance and IIFL Housing – less risky to bet on? Here’s our analysis.

Premium article available only to subscribers.

Read More
Login to your account
OR